Pfizer begins interim trials of Omicron vaccine
News » Health
Pfizer and its German partner BioNTech said on Wednesday that they have begun an interim study of a modified bivalent COVID-19 vaccine.
The Jerusalem Post reported, noting that the new vaccine also targets the Omicron strain.
However, Pfizer did not disclose which sub-variant of the Omicron strain the vaccine would target.
Follow us on Telegram
Related Posts
About The Author
Elizabeth
Elizabeth Stone has been a reporter on the news desk since 2013. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Quebec Telegram, Elizabeth Stone worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my stone@qtelegram.com 1-800-268-7116